ImmunoGen Number Of Shares Shorted vs. Price To Book
Considering ImmunoGen's profitability and operating efficiency indicators, ImmunoGen may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in May. Profitability indicators assess ImmunoGen's ability to earn profits and add value for shareholders.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
Please note, there is a significant difference between ImmunoGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunoGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunoGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
For ImmunoGen profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ImmunoGen to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ImmunoGen utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ImmunoGen's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ImmunoGen over time as well as its relative position and ranking within its peers.
ImmunoGen |
ImmunoGen Price To Book vs. Number Of Shares Shorted Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ImmunoGen's current stock value. Our valuation model uses many indicators to compare ImmunoGen value to that of its competitors to determine the firm's financial worth. ImmunoGen is rated third overall in number of shares shorted category among its peers. It is rated fifth overall in price to book category among its peers . The ratio of Number Of Shares Shorted to Price To Book for ImmunoGen is about 1,326,969 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ImmunoGen's earnings, one of the primary drivers of an investment's value.ImmunoGen Price To Book vs. Number Of Shares Shorted
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
ImmunoGen |
| = | 20.61 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
ImmunoGen |
| = | 15.53 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
ImmunoGen Price To Book Comparison
ImmunoGen is currently under evaluation in price to book category among its peers.
ImmunoGen Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ImmunoGen, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ImmunoGen will eventually generate negative long term returns. The profitability progress is the general direction of ImmunoGen's change in net profit over the period of time. It can combine multiple indicators of ImmunoGen, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate therapies to treat cancer. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. Immunogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 106 people.
ImmunoGen Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ImmunoGen. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ImmunoGen position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ImmunoGen's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in ImmunoGen without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
All Next | Launch Module |
Use Investing Themes to Complement your ImmunoGen position
In addition to having ImmunoGen in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Hedge Favorites Thematic Idea Now
Hedge Favorites
Hedge Funds pool capital from accredited individuals or institutional investors and invest in a variety of assets, often with complex portfolio-construction and risk-management techniques. The Hedge Favorites theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hedge Favorites Theme or any other thematic opportunities.
View All Next | Launch |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
Global Correlations Find global opportunities by holding instruments from different markets | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |